Business Context and Reporting Period
This Form 8-K filing by vTv Therapeutics Inc. (VTVT) is dated July 17, 2023. The report addresses the Company's status regarding its listing on the Nasdaq Capital Market following a deficiency notice related to the Minimum Bid Requirement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance and listing status.
Material Changes and Listing Status
- Deficiency Notice: On December 22, 2022, Nasdaq notified the Company that its stock price had closed below $1.00 per share for 30 consecutive business days.
- Delisting Determination: On June 21, 2023, Nasdaq determined the Company failed to regain compliance within the initial 180-day period and scheduled delisting for June 30, 2023.
- Appeal and Extension: The Company requested a hearing and submitted a compliance plan. On July 17, 2023, Nasdaq approved an extension of the compliance period until December 18, 2023.
Guidance, Outlook, and Risks
- Compliance Plan: To regain compliance, the Company represented it will effect a reverse stock split at a ratio between 1:10 and 1:20 on or before November 22, 2023.
- Shareholder Approval: The Company must obtain stockholder approval for the reverse stock split on or before October 30, 2023.
- Risks: The filing explicitly states there is no assurance that a reverse stock split will ensure compliance with the Minimum Bid Requirement. The Company cannot predict the effect of the split on the market price of its common stock.
Investor Verification Checklist
- Verify the Company's ability to secure stockholder approval for the reverse stock split by October 30, 2023.
- Monitor the execution of the reverse stock split by the November 22, 2023 deadline.
- Track the post-split stock price to ensure it meets the $1.00 Minimum Bid Requirement by December 18, 2023.
- Review upcoming filings for any updates on the Company's financial condition, as this 8-K contains no financial data.